WD-40 Company (WDFC) Is At $143.00 Formed Wedge; Fibrogen (FGEN) Sellers Increased By 1.28% Their Shorts

WD-40 Company (NASDAQ:WDFC) Logo

WD-40 Company (WDFC) formed wedge up with $148.72 target or 4.00% above today’s $143.00 share price. WD-40 Company (WDFC) has $1.99 billion valuation. The stock increased 0.14% or $0.2 during the last trading session, reaching $143. About 570 shares traded. WD-40 Company (NASDAQ:WDFC) has risen 33.54% since June 7, 2017 and is uptrending. It has outperformed by 20.97% the S&P500. Some Historical WDFC News: ; 05/04/2018 – WD-40 CO SAYS FY 18 NET INCOME IS PROJECTED TO BE BETWEEN $56.6 MLN AND $57.5 MLN; 09/04/2018 – WD-40 Will Funnel Tax Savings to Boost Digital Brand Presence; 05/04/2018 – WD 40 Sees FY18 Net $56.6M-Net $57.5M; 05/04/2018 WD 40 2Q EPS $1.05; 05/04/2018 – WD-40 SEES FY EPS $4.07 TO $4.14, EST. $3.94 (2 EST.); 05/04/2018 – WD-40 2Q EPS $1.05, EST. 95C (2 EST.); 05/04/2018 – WD-40 CO – SEES 2018 NET SALES BETWEEN $407 MLN AND $415 MLN; 05/04/2018 – WD 40 Sees FY18 EPS $4.07-EPS $4.14; 03/05/2018 – Canadian Pacific Railway, Pret A Manger, Travelex And WD-40 Among Companies To Embrace Continuous Accounting With BlackLine In; 05/04/2018 – WD 40 Sees FY18 Sales $407M-$415M

Fibrogen Inc (NASDAQ:FGEN) had an increase of 1.28% in short interest. FGEN’s SI was 2.87 million shares in June as released by FINRA. Its up 1.28% from 2.84M shares previously. With 551,800 avg volume, 5 days are for Fibrogen Inc (NASDAQ:FGEN)’s short sellers to cover FGEN’s short positions. The stock decreased 1.59% or $0.9 during the last trading session, reaching $55.7. About 34,746 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 90.24% since June 7, 2017 and is uptrending. It has outperformed by 77.67% the S&P500. Some Historical FGEN News: ; 01/05/2018 – Imperas and Andes Extend Partnership, Delivering Models and Virtual Platforms for Andes RISC-V Cores with New AndeStar V5m; 14/05/2018 – FibroGen Closes Above 200-Day Moving Average: Technicals; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018; 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 23/04/2018 – DJ FibroGen Inc, Inst Holders, 1Q 2018 (FGEN); 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY; 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 28/03/2018 – Andes Technology Corp. to Present & Exhibit at Design & Reuse IP SOC Conference

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. FibroGen Inc had 19 analyst reports since July 29, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of FGEN in report on Sunday, September 10 with “Buy” rating. The rating was initiated by Credit Suisse with “Neutral” on Thursday, January 21. Citigroup initiated it with “Buy” rating and $40 target in Friday, December 4 report. The stock has “Outperform” rating by Credit Suisse on Thursday, February 11. The company was maintained on Wednesday, October 18 by Stifel Nicolaus. As per Thursday, March 29, the company rating was maintained by Mizuho. On Monday, August 14 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Leerink Swann given on Wednesday, February 28. The firm has “Buy” rating given on Tuesday, August 8 by Jefferies. The rating was maintained by Leerink Swann with “Buy” on Tuesday, August 8.

More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Seekingalpha.com which released: “FibroGen: Strong Fundamentals, Solid Long-Term Prospects” on June 04, 2018, also Globenewswire.com with their article: “FibroGen to Present at Two Upcoming Investor Conferences” published on June 04, 2018, Nasdaq.com published: “FibroGen Announces Completion of Enrollment in US Phase 3 Clinical Program for Roxadustat in Anemia Associated …” on June 07, 2018. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Globenewswire.com and their article: “FibroGen Reports First Quarter 2018 Financial Results” published on May 09, 2018 as well as Nasdaq.com‘s news article titled: “FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable …” with publication date: June 04, 2018.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.65 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Since January 29, 2018, it had 1 buying transaction, and 3 insider sales for $856,175 activity. Shares for $214,377 were sold by HOLDSWORTH GEOFFREY on Monday, January 29. $581,278 worth of WD-40 Company (NASDAQ:WDFC) was sold by FREEMAN MICHAEL L on Tuesday, February 13. Brass Steven A sold $130,825 worth of stock or 1,000 shares. Shares for $70,305 were bought by PITTARD DANIEL E.

Analysts await WD-40 Company (NASDAQ:WDFC) to report earnings on July, 9. They expect $1.04 earnings per share, up 1.96% or $0.02 from last year’s $1.02 per share. WDFC’s profit will be $14.47M for 34.38 P/E if the $1.04 EPS becomes a reality. After $1.05 actual earnings per share reported by WD-40 Company for the previous quarter, Wall Street now forecasts -0.95% negative EPS growth.

Investors sentiment decreased to 1.15 in Q1 2018. Its down 0.14, from 1.29 in 2017Q4. It dropped, as 15 investors sold WD-40 Company shares while 57 reduced holdings. 28 funds opened positions while 55 raised stakes. 11.30 million shares or 1.27% less from 11.45 million shares in 2017Q4 were reported. Manufacturers Life Communications The invested in 0% or 10,167 shares. 47,193 were reported by Eagle Asset Mgmt Inc. Blackrock Inc stated it has 0.01% in WD-40 Company (NASDAQ:WDFC). Tortoise Invest Mgmt Ltd Liability Com reported 85 shares. Bb&T Securities Ltd Liability Co holds 74,866 shares or 0.11% of its portfolio. Renaissance Tech Limited Liability accumulated 626,600 shares or 0.09% of the stock. Synovus has 119 shares for 0% of their portfolio. Invesco Limited holds 0.01% of its portfolio in WD-40 Company (NASDAQ:WDFC) for 136,526 shares. South Dakota Investment Council invested in 3,000 shares. Rhumbline Advisers owns 0.01% invested in WD-40 Company (NASDAQ:WDFC) for 39,470 shares. Sei Invests holds 0% or 2,204 shares in its portfolio. Waratah Capital Advisors invested in 25,020 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in WD-40 Company (NASDAQ:WDFC). Stratos Wealth Partners Ltd reported 601 shares. Bb&T Corp invested 0.02% in WD-40 Company (NASDAQ:WDFC).

WD-40 Company (NASDAQ:WDFC) Institutional Positions Chart